Eric Bouteiller, formerly with Ipsen (most recently as SVP Asia PC Operations based in Beijing) and chairman of the R&D-based Pharmaceutical Association Committee (RDPAC) till December 2017, speaks in his personal capacity regarding the extraordinary changes within the Chinese healthcare and life sciences landscape. He highlights China’s dramatic pivot towards innovation in the past couple of years and how all players need to learn and adapt to new rules of the game.
Ultimately, there has been a definitive decision to shift China towards innovation
